<DOC>
	<DOCNO>NCT00191269</DOCNO>
	<brief_summary>To investigate efficacy , safety PK GEM monotherapy prior chemotherapy anthracycline taxane regimen patient metastatic breast cancer</brief_summary>
	<brief_title>Gemcitabine Monotherapy Metastatic Breast Cancer After Anthracycline Taxane Regimen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Histologically and/or cytologically confirm breast cancer Received prior chemotherapy metastatic breast cancer anthracycline taxane regimen To least one measurable region PS : 01 To adequate organ function ( bone marrow , liver renal function ) To Interstitial pneumonia pulmonary fibrosis To inflammatory carcinoma Within 28 day late chemotherapy radiotherapy , 14 day late hormonal/immunotherapy 7 day surgery To brain metastasis symptom To severe complication ( cardiac infarction , infection , drug hyper sensitivity diabetes )</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword />
	<keyword>anthracycline</keyword>
	<keyword>taxane</keyword>
	<keyword>regimen</keyword>
</DOC>